CATEGORIES: Research

THERAPEUTIC RESEARCH IN ACCELERATED DISCOVERY (TRIAD) PROGRAM REQUEST FOR PROPOSAL GUIDELINES

by | Sep 9, 2020 | 0 comments

Application Information: The Hereditary Neuropathy Foundation (HNF) would like to advance preclinical research as quickly as possible if it aligns with our key objectives. There is no application deadline. 

Average Duration: One year of support, with potential for a 12-month no-cost extension when applicable, with prior written HNF approval. Depending on the research project and met milestones,  multi-year proposals may be considered.

Average Award: Typical awards will range from $50,000 to $100,000 per year in direct cost, based on stage and scope of research. Exceptional proposals with higher budgets may be considered. We encourage multiple funding sources when applicable and they should be identified in the LOI. Per our Foundation policy, HNF will not provide indirect institutional support. 

Eligibility: Funding is open to researchers, clinicians and industry globally. Academic medical centers, universities, nonprofit and for-profit research organizations are encouraged to apply. Funding for biotechnology companies is typically set up as a venture philanthropy collaboration with a return on investment based upon agreed deliverables. 

HNF considers its application process interactive, and encourages collaboration and discussion prior to a formal submission. Interested parties should reach out to HNF via Dr. Lucia Notterpek, HNF CSO at [email protected] prior to submitting an LOI and/or a formal application. 

APPLICATION PROCESS 

  1. Letter of Intent Review

Please submit a 1-2 page letter of intent (PDF format) directly to Dr. Notterpek at  [email protected] and a copy to HNF CEO Allison Moore at [email protected]. Highlight the specific aims of the project and the milestones expected to be reached after each phase, along with the expected timelines. Identify any collaborations with companies or institutions that may advance the findings or may co-fund the project.  We will evaluate the alignment of your project with our foundation’s mission and objectives.  You will receive a response generally within four weeks. If the LOI is accepted, you will be asked to submit a full proposal  (PDF format), which will be evaluated by our Scientific Advisors. 

  1. Proposal Details
  • Lay Summary
  • Scientific Summary, Rationale and Overall objectives
  • Specific Aims
  • Background to include supporting literature and preliminary results, if available
  • Availability of tools and personnel to conduct the proposed research 
  • Experimental Plan with measurable milestones to include quarterly progress reports to HNF
  • Gantt Chart for timeframe for Completion of Experimental Plan
  • Budget justification, including personnel effort on project
  • Disclosed proposed work that may have already been funded by another advocacy group and/or funding agency 
  • NIH biosketches for the key Research Team(s) members
  • Two letters of support 

Learn more on this topic

Related Blog Posts

Sneak Peak of Fall Newsletter: CMT Research Study Survey

My name is Elizabeth Francisco and I am a graduate student from the Genetic Counseling program at the University of North Carolina Greensboro. I am inviting you to participate in a research study. The goal of my study is to learn more about the experiences of people with Charcot-Marie-Tooth (CMT) with genetic counseling and genetic testing. Adults with CMT and parents or legal guardians of someone of any age who has a diagnosis of CMT are eligible to participate

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Quality of Life and CMT Research

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Hot off the press

It seems like almost weekly there is another new publication on CMT with interesting basic biology. While an earlier “Hot off the press” highlighted the work of Cherry and co-workers at the University of Texas Southwestern Medical Center who showed show that neurons lacking a gene for rab7 result in neuropathy.

New Study on CMT Type 2B

If we are to learn more about CMT and the effectiveness of rehabilitation it is worth asking the patient and their caregiver. A recent Italian study by Padua et al recently described a survey of CMT patients and caregivers and their perspectives and perceptions of rehabilitation efficacy and needs.

Allison Moore is going to be published!

HNF’s CSO (Chief Scientific Officer), Sean Ekins wrote a blog about his work with Allison Moore and her two “fighter Mom” friends Lori Sames and Jill Wood. He named his blog: “Rare disease heroes – Extraordinary collaborators we should be listening too.” Sean helped my friends and I write a paper called: “Multifaceted roles of ultra rare and rare disease patients/parents in drug discovery.” YES, Allison Moore is going to be published! It will be in Drug Discovery Today, soon. The link to the reprint is below.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news